Homepage Top Section3

India’s Defence Research and Development Organisation (DRDO) lab Institute of Nuclear Medicine and Allied Sciences (INMAS) developed the drug in alliance with Dr Reddy’s Laboratories (DRL). The drug

Compared to placebo, vericiguat in combination with available heart failure therapies, significantly cut down the risk of heart failure hospitalisation or cardiovascular death, which was the primary endpoint

Novartis, Boehringer Ingelheim, Bristol-Myers Squibb, Eisai, Eli Lilly, Gilead, GSK, Johnson & Johnson, Merck, Pfizer, Sanofi, BD and bioMérieux are part of the consortium. The firms are working

Under the three-year collaboration, Empirico will use its Precision Insights Platform to determine therapeutic targets for indications and tissues, which are responsive to antisense technology. The Precision Insights